文献速递银屑病与炎症性皮肤病

银屑病患者帕金森病发病率与危险因素的全国人群队列研究

The incidence rates and risk factors of Parkinson disease in patients with psoriasis: A nationwide population-based cohort study.
PubMed 文献 · J Am Acad Dermatol · 2019-07-12

该全国性人群队列研究纳入银屑病患者548,327例及年龄性别匹配的无银屑病对照2,741,635例,比较帕金森病发病率与风险。结果显示银屑病组帕金森病发病风险显著升高(HR 1.091,95%CI 1.029-1.115),未接受系统治疗者风险亦升高(HR 1.093,95%CI 1.031-1.159),接受系统治疗者风险较低(HR 1.04,95%CI 0.806-1.316)。

要点

  • 银屑病患者帕金森病发病风险较无银屑病人群轻度升高(HR 1.091)。
  • 未接受系统治疗的银屑病患者帕金森病风险同样升高(HR 1.093)。
  • 接受系统抗炎治疗者风险较低,提示系统性抗炎治疗可能降低该风险。

核心结论

  • 银屑病患者帕金森病发病风险显著升高,系统性抗炎药物可能减轻该风险。

研究设计与样本

  • 全国性人群基础队列研究,纳入银屑病患者548,327例(≥20岁,男53.32%、女46.68%)及年龄性别匹配对照2,741,635例。

主要发现

  • 帕金森病每1000人年发病率在对照组为0.673、银屑病组为0.768。
  • 银屑病组发生帕金森病的风险显著升高(HR 1.091,95%CI 1.029-1.115)。
  • 未接受系统治疗的银屑病患者风险显著升高(HR 1.093,95%CI 1.031-1.159)。
  • 接受系统治疗的银屑病患者风险较低(HR 1.04,95%CI 0.806-1.316)。

临床怎么用

  • 对银屑病患者应关注帕金森病相关神经系统症状,尤其未接受系统治疗者。
  • 系统抗炎治疗可能有助于降低帕金森病风险,可作为临床决策的参考信息。

局限性

  • 回顾性设计。
  • 仅依据诊断编码纳入患者。
  • 缺乏混杂因素数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between psoriasis and Parkinson disease has not been established. OBJECTIVE: To determine the incidence rates and risk factors of Parkinson disease in patients with psoriasis. METHODS: We conducted a nationwide population-based cohort study. The data from patients with psoriasis (N = 548,327, ≥20 years of age, 53.32% men and 46.68% women) and age- and sex-matched control patients (N = 2,741,635) without psoriasis were analyzed in this study. RESULTS: The incidence rates of Parkinson disease per 1000 person-years were 0.673 and 0.768 in the control and psoriasis groups, respectively. The psoriasis group showed a significantly increased risk of developing Parkinson disease (hazard ratio [HR] 1.091, 95% confidence interval [CI] 1.029-1.115). The risk of Parkinson disease was significantly higher among the psoriasis patients who were not receiving systemic therapy (HR 1.093, 95% CI 1.031-1.159) and lower among the psoriasis patients on systemic therapy (HR 1.04, 95% CI 0.806-1.316). LIMITATIONS: The limitations of this study included the retrospective design, patient inclusion solely on the basis of diagnostic codes, and unavailability of data on confounding factors. CONCLUSION: Systemic anti-inflammatory agents might mitigate the risk of Parkinson disease in psoriasis patients.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Lee JH, Han K, Gee HY, et al. The incidence rates and risk factors of Parkinson disease in patients with psoriasis: A nationwide population-based cohort study. J Am Acad Dermatol. 2019. PMID: 31302182. doi:10.1016/j.jaad.2019.07.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。